×
Click here if your patients are having issues using their co-pay card or their co-pay is higher than normal at the pharmacy.

Indication Aimovig® is indicated for the preventive treatment of migraine in adults.

In person or via telemedicine, the resources to help start your patients on Aimovig® are right here

We have gathered resources you may find helpful to start and support patient treatment with Aimovig®.
1

Starting patients on Aimovig®

Helping your patients get resources to start Aimovig®

Guide on helping patients start Aimovig® (erenumab-aooe)
Getting Started Guide
A single resource guide, highlighting patient programs and tools to help patients new to Aimovig® start and stay on treatment as prescribed.
Aimovig® (erenumab-aooe) Copay Card
Aimovig® Copay Card
Your commercially insured eligible patients can get Aimovig® for as little as a $5 monthly copay.
Up to program maximums. Terms and Conditions apply. Click here for details.
Aimovig® (erenumab-aooe) injection guides for 70 mg and 140 mg
Dosing Reference Guides_mobile
Injection Reference Guides
Aimovig® is available in once-monthly doses of 70 mg and 140 mg.1 Download a quick overview of how to inject Aimovig.
The 70 mg and 140 mg Instructions for Use and the Aimovig®Injection Video may also be helpful tools for your patients.
2

Tools to help get your patients covered

Aimovig® offers different options based on insurance coverage

  • With the Aimovig® Copay Card, commercially insured eligible patients can pay as little as a $5 copay per month. Up to program maximums. Terms and Conditions apply. Click here for details
  • Eligible commercially insured patients may be able to receive a 90-day supply of Aimovig® based on plan coverages
  • For uninsured and under-insured patients, Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost. Learn more here

Here are a few resources and forms that may be helpful for gaining access to Aimovig®.

Prior authorization support for Aimovig® (erenumab-aooe)
Prior Authorization Support
Prior Authorizations can be filed through your preferred EHR platform.
Access our PA checklist.
Sample letter of appeal
Sample Letter of Appeal
Template to request a review of a denied claim for Aimovig®.
Sample letter of medical necessity
Sample Letter of Medical Necessity
Template to file documentation that Aimovig® is medically necessary.
3

Telemedicine resources

The use of telemedicine and remote care services to treat patients has been increasing over time and, in some situations, may be essential. Here are a few telemedicine and remote care resources that you may find valuable.

The use of telemedicine and remote care services to treat patients has been increasing over time and, in some situations, may be essential. Here are a few telemedicine and remote care resources that you may find valuable.

AAN guidance on telemedicine and remote care:

Disclaimer: These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Amgen of any of the products, services, or opinions of the organization or individual. Amgen bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.

Have more questions?
Simply call 1-833-AIMOVIG (833-246-6844), Monday-Friday, 8:00 am-9:00 pm ET. You’ll receive live support for your questions from knowledgeable representatives.

SUMMARY OF TERMS AND CONDITIONS

It is important that every patient read and understand the full Aimovig® (erenumab-aooe) Copay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.

As further described in the full terms and conditions, in general:

  • The Aimovig® Copay Card is open to patients with commercial insurance, regardless of financial need. The program is not valid for patients whose Aimovig® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law.
  • With the Aimovig® Copay Card, a commercially insured patient who meets eligibility criteria may pay as little as a $5 copay per month for their Aimovig® monthly out-of-pocket costs. Monthly out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient up to a Maximum Monthly Benefit, a Maximum Annual Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed these limits.
  • The program provides assistance up to a Maximum Monthly Benefit except that the Maximum Monthly Benefit will not apply to the first 2 uses of the Aimovig® Copay Card for Aimovig® in any given calendar year.
  • Offer is subject to change or discontinuation without notice.
  • The Aimovig® Copay Card provides support up to the Maximum Monthly Benefit, the Maximum Annual Program Benefit and/or Patient Total Program Benefit. If a patient’s commercial insurance plan imposes different or additional requirements on patients who receive Aimovig® Copay Card benefits, Amgen has the right to reduce or eliminate those benefits. Whether you are eligible to receive the Maximum Monthly Benefit, Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Aimovig Ally™ representative to help you understand eligibility for the Aimovig® Copay Card, and whether your particular insurance coverage is likely to result in your reaching the Maximum Monthly Benefit, the Maximum Annual Program Benefit, or your Patient Total Program Benefit, by calling 1-833-AIMOVIG (833-246-6844).
  • Please see the full Terms and Conditions at www.aimovigcopaycard.com/tcs.

INDICATION

Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe 

References: 1. Aimovig® (erenumab-aooe) Prescribing Information. Thousand Oaks, CA; Amgen Inc: 2021. 2. Data on file, Amgen; 2023.